| Q3 FY26 Earnings Conference Call
Summary : Thyrocare delivered strong Q3 FY'26 results, driven by robust franchisee and partnership growth, strategic investments in specialty diagnostics, and international expansion, despite seasonal demand.
Management Perspective positive : Pleased to share Thyrocare onboarded Madhuri Dixit as brand ambassador.Franchise business continues as a key growth driver.Happy to announce achieving set benchmark for complaint reduction.Delivered strong financial performance with consistent revenue growth.
Concall Report Analysis & Insights
Business Overview
- Q3 FY'26 revenue grew 18% year-on-year to INR196 crores.
- Processed 49.6 million tests, up 22% year-on-year, serving 4.5 million patients.
- Franchisee business grew 12% year-on-year, reaching 10,300 active franchisees.
- Partnerships business grew 39% year-on-year, driven by new health tech clients.
- Achieved 100% NABL accreditation and reduced complaints by 43% year-on-year.
Future Growth Prospects
- Expanding into Africa, starting with Tanzania, aiming for breakeven in 12-18 months.
- Investing heavily in specialty diagnostics, including new labs and field force.
- Expanding test menu with 100-plus SKU menu on Phadia platform.
- Flagship brands Aarogyam and Jaanch growing at 16% year-on-year.
- Expects mid-teens consolidated growth rate long-term.
Management Insights
- Committed to affordable, high-quality diagnostics with on-time reports.
- Maintains strategy as the B2B partner of choice for diagnostic services.
- Focus on operational excellence, franchisee growth, and continuous improvement.
- Invests in technology, quality systems, and test menu expansion.
- Onboarded Madhuri Dixit as brand ambassador to communicate quality.
Signs of Skepticism
- Analyst questioned sustainability of 15% growth given market size.
- Analyst inquired about sustainability of PharmEasy's business uptick.
- Analyst questioned lower tax rate and its sustainability for Q4.
- Analyst sought clarity on ROU accounting impact on gross margin.
Risk Factors
- Softer demand during Q3 due to festivals and seasonality.
- Vimta business underperformed due to tighter credit controls.
- Sustaining high growth rates on a larger base requires significant investment.
- Building awareness for new tests like GLP-1 takes time.
Good To Know
- Welcomed Dr. Ramesh Kinha as COO and Rajdeep Panwar as CCO.
- Recognized as Best Diagnostic Lab Chain and Patient-Centric Company.
- Launched in-house allergy testing, included free in Aarogyam packages.
- Average report turnaround time is 3.28 hours from sample receipt.
- Lab network expanded to 39 labs in India and 1 in Tanzania.
Key Drivers
- Franchisee network expanding rapidly.
- Partnership business shows strong growth.
- New specialty offerings drive revenue.
- Africa expansion provides new markets.
Key Analyst Discussions
Competitive Environment
- Questions on Thyrocare's B2B value proposition and competitive lead.
- Inquiries about dedicated phlebotomy fleet and technology platform advantages.
- Discussion on market growth rates and peer performance.
Market Trends & Consumer Behavior
- Questions regarding the uptake of GLP-1 related diagnostic tests.
- Discussion on softer demand due to festivals and seasonality in Q3.
- Inquiry about revenue per test decline due to sugar test discounts.
Financial Highlights
- Questions on ROU capitalization impact on depreciation and COGS.
- Inquiries about total capex for the current financial year.
- Discussion on sustainability of 75-76% gross margin.
- Clarification on lower tax rate and its future impact.
Product Composition
- Questions about specific tests included in GLP-1 packages.
- Discussion on the growth of Aarogyam and Jaanch packages.
- Inquiry about the expansion of specialty offerings.
Strategic Considerations
- Questions on the sustainability of partnership business growth.
- Inquiries about the strategy for Tanzania and broader Africa expansion.
- Discussion on credit policy tightening affecting Vimta business.
- Clarification on revenue recognition for franchisee vs. partnership models.